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Abstract
Background: Previous research reviewed treatment success and whether the collective uncertainty principle is met
in RCTs in the US National Cancer Institute portfolio. This paper classifies clinical trials funded by the UK HTA
programme by results using the method applied to the US Cancer Institute trials, and compares the two portfolios.
Methods: Data on all completed randomised controlled trials funded by the HTA programme 1993-2008 were
extracted. Each trial’s primary results was classified into six categories; 1) statistically significant in favour of the new
treatment, 2) statistically significant in favour of the control treatment 3) true negative, 4) truly inconclusive, 5)
inconclusive in favour of new treatment or 6) inconclusive in favour of control treatment. Trials were classified by
comparing the 95% confidence interval for the difference in primary outcome to the difference specified in the
sample size calculation. The results were compared with Djulbegovic’s analysis of NCI trials.
Results: Data from 51 superiority trials were included, involving over 48,000 participants and a range of diseases
and interventions. 85 primary comparisons were available because some trials had more than two randomised
arms or had several primary outcomes. The new treatment had superior results (whether significant or not) in 61%
of the comparisons (52/85 95% CI 49.9% to 71.6%). The results were conclusive in 46% of the comparisons (19%
statistically significant in favour of the new treatment, 5% statistically significant in favour of the control and 22%
true negative). The results were classified as truly inconclusive (i.e. failed to answer the question asked) for 24% of
comparisons (20/85). HTA trials included fewer truly inconclusive and statistically significant results and more results
rated as true negative than NCI trials.
Conclusions: The pattern of results in HTA trials is similar to that of the National Cancer Institute portfolio.
Differences that existed were plausible given the differences in the types of trials -HTA trials are more pragmatic.
The results indicate HTA trials are compatible with equipoise. This classification usefully summarises the results from
clinical trials and enables comparisons of different portfolios of trials.
Background
Ethically an RCT should only be undertaken if clinicians
are truly unsure which of the interventions being com-
pared is more likely to benefit patients [1,2]. This concept
is referred to as equipoise or the collective uncertainty
principle [1,3]. The “equipoise hypothesis” implies a pre-
dictable relationship between equipoise and the ultimate
outcomes of trials [4,5]. Given a random unbiased sample
of trials, no significant difference would be expected in
the proportion favouring the new treatment to the pro-
portion favouring the standard treatment [3,6,7].
The pattern of results and satisfaction of equipoise in a
cohort of RCTs from the US National Cancer Institute
portfolio [3,8-10] was reviewed by Djulbegovic et al cov-
ering 743 National Cancer Institute trials conducted
1955-2000. They classified the primary outcome trial
results into one of six categories based on whether they
included an important difference in favour of the new or
standard treatment [8] 24% of trial results had statisti-
cally significant results in favour of the new treatment
and the new treatment was favoured by the researchers
in 41% of comparisons. They concluded that about 25%
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successful. Soares, Kumar and Joffe conducted similar
reviews on NCI trials with similar results [3,9,10]. Djulbe-
govic et al were the only authors to apply the six category
classification of primary outcome results.
Johnson et al found most people would accept an RCT
to be ethical if the probability of success of a new treat-
ment is between 50% and 70% [11]. Djulbegovic et al
found most members of an institutional review board
would approve a trial with expected probability of success
of a new treatment between 40% and 60% [12].
The Health Technology Assessment programme
(HTA) of the National Institute for Health Research is
the leading public funder of randomised controlled trials
(RCTs) in the NHS [13,14]. It funded and published the
results of 74 trials between 1993- 2008. These trials aim
to answer questions of importance to the NHS, usually
evaluate cost as well as clinical effectiveness and inform
N I C Ed e c i s i o n s .T h et r i a l si n v o l v eaw i d er a n g eo fi n t e r -
ventions, areas of health and usually include patient
reported outcomes.
This paper classifies the HTA trials by results using
the classification developed by Djulbegovic et al [8].
Aims
1. To classify HTA superiority trials by results using
Djulbegovic’s classification
2. To compare the results with those from the simi-
lar classification of NCI trials
Methods
Trials included
All randomised controlled trials (RCT) funded by the
HTA programme were eligible for inclusion in the study
(13). The trial had to have had a superiority design and
have published their results by May 2008. Trials were
excluded if the primary outcome results were unclear or
lacked a confidence interval. Comparisons were excluded
if it was unclear which trial arm was the control.
Data extracted
We extracted data on each trial from the HTA journal
series publication on: trial design, trial interventions, no.
of arms, primary outcome(s), primary time point, sample
size calculation parameters including the minimum clini-
cally important difference that the trial aimed to detect,
sample size planned and achieved and primary outcome
results from the primary time point including 95% confi-
dence interval (CI) for the treatment difference (defined
as the primary comparison).
We defined the primary outcome as:
“Primary outcome - Main outcome(s) of interest, in
the following hierarchical order:
1. Explicitly defined as primary or main
2. Outcome used in the power calculation
3. Main outcome stated in the trial objectives”
Chan et al [15].
The primary timepoint was defined similarly:
“Primary time point - Main follow up timepoint(s) of
interest, in the following hierarchical order:
1. Explicitly defined as primary or main follow up time
point of interest
2. Time point specified in the power calculation
3. Main follow up timepoint stated in the trial
objectives
If the authors didn’t state a primary timepoint we
defined it as the first follow up time point for the primary
outcome. The first timepoint was selected because this is
when the trial was expected to have greatest power (as
smallest loss of participants). As this could bias our analy-
sis in favour of more conclusive results we also conducted
a sensitivity analysis selecting the last follow up time point
for the primary outcome as “primary timepoint”.
If the authors included a number of sample size calcu-
lations for the primary outcome (for example because
they had re-estimated the required sample size part way
through the trial), the smallest clinically meaningful dif-
ference specified in the calculations was extracted.
Data extraction process
Data was extracted by a research assistant and 100%
checked by LD. Discrepancies were resolved by discus-
sion with JR.
Classification of data
We classified each of the trial intervention arms as either
new/experimental intervention or the control/standard
intervention. An intervention was defined as the control
intervention if it was described by the authors in the
journal series as either “standard care, usual care, control,
placebo or the intervention used most frequently in the
NHS”. A public health consultant independent of the
project team, Andrew Cook, checked the classification.
For each trial primary comparison, we classified the
results into one of the six categories developed by Djulbe-
govic et al 1) statistically significant in favour of the new
treatment, 2) statistically significant in favour of the con-
trol treatment 3) true negative, 4) truly inconclusive,
5) inconclusive in favour of new treatment or 6) inconclu-
sive in favour of the control treatment [8]. We decided
which category by comparing the 95% confidence interval
for the difference in primary outcome to the difference
specified in the sample size calculation. See figure 1 for an
illustration of which category was assigned in each situa-
tion. The results were classified as true negative if the 95%
confidence interval excluded a meaningful difference in
either direction implying the treatments have similar effect
(figure 1). The results were classified as truly inconclusive
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either direction (i.e. trial failed to answer the primary
question).
For example, one of the trials examined the effective-
ness of short-term counselling in general practice for
patients with chronic depression or combined depression
and anxiety, compared with general practitioner (GP)
care alone. The primary outcome of the trial was the
Beck Depression Inventory (BDI) and the sample size cal-
culation specified the minimum important difference in
BDI was 3.5 with a lower BDI score implying better out-
come. The primary results at 12 months found the mean
difference in BDI score between counselling and GP care
alone was 1.18 with a 95% confidence interval of -1.56 to
3.92. This result was classified as “Inconclusive in favour
of control” the last row in figure 1. This is because “d”
for this trial was -3.5 (the aim with the intervention was
that it would reduce BDI score but it actually increased it
on average very slightly and the confidence interval
included an increase of 3.5 points).
We used the difference from the sample size calcula-
tion rather than the surrogate (global proxy) of 0.8 and
1.2 used by Djulbegovic for three reasons. First, the pri-
mary outcome in the HTA trials was rarely a hazard
ratio, odds ratio or relative risk, unlike in the NCI trials.
If the primary outcome results were presented as an
odds ratio, hazard ratio or relative risk and a minimum
important difference in relation to these wasn’td i s -
cussed in the sample size calculation then we used 0.8
and 1.2 as a proxy for a clinically meaningful difference
as per Djulbegovic et al.
Second, it can be argued that the difference specified
by the original researchers in the sample size calculation
represents a minimum important difference. This may
not always be true, as investigators may specify a differ-
ence relating to the sample size they can achieve [16].
However, as the average effect size the trials aimed to
detect was 0.29, considered small by Cohen (range 0.06
to 0.67, median 0.28, inter-quartile range 0.18 to 0.40),
we believe this is not true with these trials.
Statistically significant in favour of control treatment 
Statistically significant in favour of new treatment 
True negative 
Truly inconclusive (equal chance that control treatment
better than new or vice versa) 
-d d 0
Favours new treatment  Favours control treatment 
Inconclusive in favour of new treatment 
Inconclusive in favour of control treatment 
Figure 1 Classification of RCT results based on 95% confidence interval and minimum important difference from the trial sample size
calculation (d). 1. Explanation of the labels: The label given to each result are the labels used by Djulbegovic et al [8]. The labels assigned to
the two inconclusive categories have been slightly amended from that used by Djulbeovic. 2. Explanation of -d and d: Djulbegovic’s method
used -d = 0.8 and d = 1.2 for all trials reviewed because all outcomes they evaluated were binary and expressed as a hazard ratio, odds ratio or
relative risk. The value used for -d and d in this review was the minimum important difference specified in the sample size calculation from each
trial. For example if the sample size calculation for a trial indicated an increase of 5 points was the minimum important difference for the
primary outcome then -d was equal to -5 and d was equal to 5. 3. If the primary outcome result was expressed as a Hazard Ratio, Relative Risk
or Odds Ratio then zero in this figure is replaced with 1.
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difference specified is more reliable than converting all
trial results to a common outcome and using a global
proxy.
One of the trials resulted in 12 primary comparisons
because it had 6 domains of SF36 as primary outcome
and two active arms, both being compared to a control
arm. To ensure this trial didn’td o m i n a t er e s u l t sw e
conducted a sensitivity analysis including 2 primary
comparisons for this trial one for each comparison of
active arm to control. We selected the two primary
comparisons as those relating to the category which
applied most frequently.
Analysis of data
We summarised the characteristics of the trials and
comparisons included. We calculated the proportion of
trials which achieved the required sample size and 80%
of the required sample size.
We calculated the proportion of comparisons which
favoured the new treatment and the proportion which
favoured the control treatment (regardless of whether
the results were statistically significant). We calculated
an exact binomial 95% CI for the proportion of treat-
ments which favoured the new intervention [17]. If the
95% CI included 50% we concluded the results were
consistent with equipoise [3].
We calculated the percentage of comparisons in each
of the six categories and from this the percentage of
comparisons which were conclusive. A comparison was
defined as conclusive if it was either statistically signifi-
cant or true negative (categories 1, 2 or 3 in Figure 1).
We compared the percentage of trial results in each
category to the percentage in each category from the
Djulbegovic analysis of NCI trials [8].
We conducted a sensitivity analysis including trial
results that related to the longest follow up for trials
which didn’t specify a primary time point and including
2 results only for the trial which involved 12 primary
comparisons.
Results
Included and excluded RCTs
Between 1993 and May 2008 the UK HTA programme
funded and published the results from 74 RCTs in the
HTA monograph series in which all its trials are
reported [18]. Of the 74 trials, thirteen were excluded
because they were equivalence or non-inferiority trials
and a further ten because relevant data were not avail-
able (figure 2).
Characteristics of included RCTs and comparisons
The 51 superiority trials which involved over 48,000
participants had 85 primary comparisons because some
included more than two randomised arms or had several
primary outcomes (additional file 1, appendix 1 shows
the breakdown of comparisons to trials).
The characteristics of the trials and comparisons are
shown in tables 1-2 (and additional file 2, appendix 2).
Most trials were parallel design (96%) and involved 2
arms (75%). The trials evaluated a wide range of inter-
ventions and diseases. Service delivery and surgery were
the most frequent type of intervention evaluated (22%
and 16% respectively). The disease investigated in 48%
of the trials were diseases of the nervous system, circula-
tory system and musculoskeletal system and connective
tissue. The most frequent type of primary outcome used
in the trials was a symptom score or measurement of
depression/pain. The median number of participants in
RCTs included  
(n = 51) 
RCTs that had published 
results in HTA journal 
series by May 2008  
(n= 74 in 63 
monographs) 
RCTs excluded (n = 10)  
   
Primary outcome results did not 
include a confidence interval (n=5) 
No clear or relevant results on 
primary outcome reported (n=3) 
Primary outcome in sample size 
calculation didn’t match results        
(n = 1) 
Wasn’t possible to identify control 
treatment as both commonly used 
(n=1) 
RCTs with superiority 
design framework 
published in HTA 
journal series by May 
2008 (n= 61) 
RCTs excluded (n = 13)  
  
    Equivalence trial (n=10) 
  Non-inferiority  trial  (n=3) 
No. of primary 
comparisons from the 51 
RCTs (n=92)  Primary comparisons excluded (n = 7)  
   
Wasn’t possible to identify control 
treatment as both treatments in the 
comparison were new (n=7)  No. of primary 
comparisons included 
from these 51 RCTs 
(n=85) 
Figure 2 Included and excluded RCTs and comparisons.
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of their planned sample size. Most trials performed an
intention to treat analysis (94%), but in 3 trials the ana-
lysis population used was unclear. Blinding was fre-
quently not possible and most trials didn’tb l i n d
participants (96%), the person administering the inter-
vention (98%) or the outcome assessor (75%). Of the 13
which blinded the outcome assessor, a number reported
this was not always successful because they could not
stop the participant revealing the intervention to the
assessor.
Trial results
Across all comparisons, the new treatment had superior
results (whether significant or not) in 61% of the com-
parisons (52/85), with 95% exact confidence interval
Table 1 Characteristics of the 51 included trials
Characteristic No. of trials (%)
Study design
Parallel 49 (96)
Factorial 2 (4)
Number of arms
2 arms 38 (75)
3 arms 8 (16)
4 arms 2 (4)
5 arms 3 (6)
No. of participants
Total number of participants in all trials 48,323
Mean number of participants per trial
(excluding outlier involving 14,802 participants)
670
Median number of participants per trial (IQR) 457 (212 to 806)
Trials achieving sample size
Trials achieving at least required sample size 18 (35%)
Trials recruiting 80% of original target 34 (67%)
Intervention evaluated
Service Delivery 11 (22)
Surgery 8 (16)
Psychological Therapy 5 (10)
Physical Therapies 5 (10)
Diagnostic 5 (10)
Drug 4 (8)
Devices 4 (8)
Social Care 3 (6)
Education and Training 2 (4)
Complementary Therapies 2 (4)
Vaccines and Biologicals 1 (2)
Diet 1 (2)
Disease (ICD10 chapter)
M00-M99 Diseases of the musculoskeletal system
and
connective tissue
8 (16)
G00-G99 Diseases of the nervous system 8 (16)
I00-I99 Diseases of the circulatory system 8 (16)
Z00-Z99 Factors influencing health status and
contact with
health services
6 (12)
F00-F99 Mental and behavioural disorders 6 (12)
O00-O99 Pregnancy, childbirth and the puerperium 4 (8)
K00-K93 Diseases of the digestive system 3 (6)
N00-N99 Diseases of the genitourinary system, 3 (6)
C00-D48 Neoplasms 2 (4)
LOO-L99 Diseases of the skin and subcutaneous
tissue
1 (2)
P00-P96 Certain conditions originating in the
perinatal
Period
1 (2)
S00-T98 Injury, poisoning and certain other
consequences
of external causes
1 (2)
Primary outcome types in the 51 trials*
Symptom score or measurement of
depression/pain
13 (25)
Table 1 Characteristics of the 51 included trials
(Continued)
Quality of life measure (including generic and
disease specific)
10 (19)
Positive event rate (e.g. improvement in
symptoms)
10 (19)
Adverse event rate (e.g. post operative nausea
and vomiting)
9 (17)
Survival/mortality 6 (11)
Measurement of function 4 (8)
Other 1 (2)
Intention to treat analysis
Yes 48 (94)
No 0 (0)
Unclear 3 (6)
Blinding / Masking
Participant blinded 2 (4)
Outcome assessor blinded 13 (25)
Person administering intervention blinded 1 (2)
No blinding 38 (74)
Combination of blinding / masking
Participant and outcome assessor blinded only 2 (4)
Administrator and outcome assessor blinded
only
1 (2)
Outcome assessor blinded only 10 (20)
No blinding 38 (74)
*This adds up to 53 because two trials included 2 different types of primary
outcome
Table 2 Characteristics of the 85 comparisons from the
51 included trials
Characteristic No. of comparisons (%)
Type of comparison
One active treatment vs. other active
treatment
72 (85)
Active treatment vs. placebo/no
treatment
13 (15)
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50% implying the results are compatible with equipoise
(as per Kumar’s hypothesis) [3]. The confidence interval
is also compatible with Djulbegovic et al and Johnson
et al’s suggested range for an RCT to be ethical [11,12].
Overall, 46% of comparisons were conclusive (figure 3
categories 1, 2 and 3). Twenty four percent of results were
statistically significant (20/85), of which 80% favoured the
new treatment and 20% the control. Twenty two percent
were rated as true negative with the 95% confidence inter-
val excluding the possibility of an important difference in
either direction. The results were classified as truly incon-
clusive for 24% of comparisons (20/85). For these compar-
isons the 95% confidence interval still included the
possibility of an important difference in either direction.
Of the 20 truly inconclusive comparisons, twelve were
from trials which failed to recruit the planned sample
size, 5 of which failed to recruit 80% of their target. A
similar percentage failed to recruit across the other cate-
gories so failing to recruit cannot be concluded as the
sole reason these trial results were truly inconclusive.
Sensitivity analysis
The sensitivity analyses show that the percentage of
comparisons included in each category does not change
significantly depending on whether the shortest or long-
est follow up results were included or if the number of
comparisons for one trial were reduced (figure 4). The
results are therefore not sensitive to inclusion criteria.
Comparison to NCI results
Comparing the percentage of results in each category to
the review of NCI trials shows, HTA trials involved pro-
portionally fewer trials with statistically significant results,
fewer trials with truly inconclusive results and more trials
with “True Negative” results (figure 4, table 3) (statistically
significant comparisons - 34% NCI vs. 24% HTA, “Truly
inconclusive” comparisons - 33% NCI (218/654) versus
24% HTA (20/85), “True negative” comparisons - 2% NCI
(12/654) versus 22% HTA (19/85)).
Discussion
What we found
In the HTA trials we found a similar proportion of
results favouring the new treatment as in the analysis of
the NCI trials. Approximately half of the primary results
were conclusive and a quarter were truly inconclusive.
HTA trials included fewer truly inconclusive and statis-
tically significant results and more results rated as true
negative than NCI trials.
 
74 HTA funded 
RCTs published by 
May 2008 
 
85 comparisons 
across 51 trials 
included 
Positive results 
(statistically 
significant)  
24% (n=20) 
Favoured control 
intervention  
20% (n=4) 
Favoured new 
intervention 
80% (n=16) 
Negative results  
(not statistically 
significant)  
76% (n=65) 
True negative  
(no difference) 
29% (n=19) 
Inconclusive  
in favour of new 
intervention 
23% (n=15) 
Truly inconclusive 
(equal chance that 
control intervention 
better than new or 
vice-versa)         
31% (n=20)
Inconclusive in 
favour of control 
intervention 
17% (n=11)  
 
23 trials excluded  
(no data available or 
non-inferiority / 
equivalence trials) 
7 comparisons 
excluded 
Figure 3 Classification of primary outcome results of the HTA trials.
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T h i si st h ef i r s ts t u d yt h a tw ea r ea w a r eo ft oa s s e s s
treatment success and equipoise in a cohort of prag-
matic RCTs. Publication bias did not apply as all HTA
funded trials are published in the open access HTA
monograph series regardless of study results.
Our study has limitations. Firstly, HTA trials often
include multiple primary outcomes which are measured
at multiple time points. Therefore, selecting which trial
result was the primary was not always straight forward.
However, having access to a comprehensive report of the
trial meant we had access to all the data and trial results.
Where there was uncertainty a sensitivity analysis was
performed and showed that this made no difference to
the main results.
Second our analysis kept the primary outcome results
in the original unit of measurement and compared them
to the difference specified by the original researchers in
the sample size calculation. We assumed that the differ-
ence specified by the original researchers in the sample
size calculation represents the minimum important dif-
ference for that outcome in that population. There is
0%
5%
10%
15%
20%
25%
30%
35%
Statistically
significant in
favour of
control
Statistically
significant in
favour of
new
True
negative
Inconclusive
in favour of
new
Truly
inconclusive
Inconclusive
in favour of
control
%
 
o
f
 
c
o
m
p
a
r
i
s
o
n
s
 
HTA short follow up (n=85 comparisons)
HTA short term follow up with 2 comparisons for 12 comparison trial (n=75)
HTA long term follow up (n=85 comparisons)
HTA long term follow up with 2 comparisons for 12 comparison trial (n=75)
NCI Trials reviewed by Djulbegovic et al (n=654 comparisons)
Figure 4 Primary outcome results of the HTA trials compared to NCI trials with sensitivity analysis.
Table 3 Table of results used to produce figure 4
NCI Trials
reviewed by
Djulbegovic
et al
(n = 654
comparisons)
HTA short
follow up
(n = 85
comparisons)
HTA short follow
up with
2 comparisons for
12 comparison
trial (n = 77)
HTA long term
follow up
(n = 85
comparisons)
HTA long term
follow up with
2 comparisons for
12 comparison
trial (n = 75)
Classification / category N % n % n % n % n %
1. Statistically significant in favour of control 45 7% 4 5% 4 5% 4 5% 4 5%
2. Statistically significant in favour of new 176 27% 16 19% 15 20% 13 15% 13 17%
3. True negative 12 2% 19 22% 16 21% 18 21% 16 21%
4. Inconclusive in favour of new 84 13% 15 18% 12 16% 21 25% 14 19%
5. Truly inconclusive 218 33% 20 24% 18 24% 19 22% 18 24%
6. Inconclusive in favour of control 119 18% 11 13% 10 13% 10 12% 10 13%
Total 654 100% 85 100% 75 100% 85 100% 75 100%
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case, with investigators specifying the difference relating
to the sample size they can achieve [16]. However, as the
average effect size the trials aimed to detect was 0.29,
considered small by Cohen (range 0.06 to 0.67, median
0.28, inter-quartile range 0.18 to 0.40), we believe this is
not true with these trials. Further, we believe using the
actual important difference specified is more reliable
than converting all trial results to a common outcome
and using a global proxy.
Comparison with other studies
Our results were similar to previous reviews of oncology
RCTs [8-10,16,19-21]. Where differences exist these
seem to be justified given the differences in the types of
trials funded by HTA and NCI. HTA trials are generally
more pragmatic than NCI trials [22].
By comparison with the NCI trials in Djulbegovic et al,
HTA trials included fewer truly inconclusive and statisti-
cally significant results and more results rated as true
negative. Three reasons might explain these differences.
Firstly, the HTA trials were on average almost twice as
large as the trials included in the NCI cohort (mean
number of participants 670 for HTA trials and 347 for
NCI trials). A larger sample size results in narrower con-
fidence intervals which could account for why HTA trials
have more results graded as true negative instead of truly
inconclusive when compared to NCI trials. Secondly,
these narrow CI’s are more likely to be centred around a
smaller difference in HTA trials because their pragmatic
nature conducted in a real life NHS setting dilutes any
treatment effect. This could be why there are fewer statis-
tically significant results and more true negative results in
HTA trials than NCI trials. Thirdly, the method used to
assign each trial result to one of the six categories was
slightly different; Djulbegovic used a global proxy for an
important difference whereas we used a trial specific
measure where possible.
Meaning of the study
The fact that only 24% of the HTA trial results were sta-
tistically significant is similar to other studies. Djulbego-
vic, Joffe, Kumar and Soares who reviewed National
Cancer Institute trials found the percentage of statisti-
cally significant results was 34% (221/654), 32% (33/103),
29% (44/152), and 12% (7/52) respectively [3,8-10]. Of
those the percentage which favoured the experimental
treatment was 80% (176/221), 90% (30/33), 72% (32/44)
and 86% (6/7) respectively. All of these studies concluded
the results were consistent with equipoise.
Just over half of the HTA trials reviewed and three
quarters of NCI trials had inconclusive results. A trial
r e s u l tc o u l db ei n c o n c l u s i v ed u et oo n eo rm o r eo ft h e
following reasons:
1. If the trial didn’t recruit the planned sample size
2. If the difference observed was smaller than differ-
ence the trial aimed to detect (as specified in the sample
size calculation)
3. If the variability in primary outcome was greater
than anticipated in the sample size calculation or the
control group event rate was larger than anticipated in
the sample size calculation (both of which would require
a larger sample size than planned)
4. If a significant difference wasn’to b s e r v e ds i m p l y
due to chance. Most trials are powered in the sample
size calculation for 80% power which implies there is a
1 in 5 chance the trial wont find a statistically significant
difference if it exists.
Djulbegovic stated that the reasons for such a large num-
ber of truly inconclusive NCI trials was not entirely clear,
but did not appear to be due to accrual problems but due
to the overly optimistic size of the treatment effect that
they designed their trials to measure (hence the trials were
not designed to be big enough to detect important differ-
ences) [8]. The reason for such a large number of trials
having truly inconclusive results in HTA also does not
appear to be solely due to accrual problems as a similar
percentage of trials with conclusive results as inconclusive
results failed to recruit to target. In trials which recruited
the required sample size but still had inconclusive results
the difference observed must either have been smaller than
expected or variability greater (situations 2 to 4 above).
Unanswered questions and further research
Further work might usefully review the conclusions of
HTA trials with truly inconclusive results and undertake
a literature search to assess whether another trial is
needed to answer the question.
This study focused solely on the clinical primary out-
come results and did not consider other outcomes or
economic analysis results which are important in HTA
trials. Previous research has assessed equipoise in a num-
ber of ways including converting all results to the same
scale and applying meta-analysis and reviewing trial con-
clusions. Our study did not apply these methods because
we were keen to keep the results in the original scale of
measurement and not lose their meaning and because of
the additional complexity of conclusions in relation to
health economic analyses conducted in HTA trials.
Further research in this area could usefully systematically
review the authors conclusions about which intervention
was preferred which would take into account multiple
outcomes, benefits, harms and costs of each intervention.
Further work might also systematically review the eco-
nomic results of these trials and compare them with the
clinical results.
The seemingly low success rate predicted by the equi-
poise hypothesis and observed in this and Djulbegovic
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Page 8 of 10[8], only applies to publicly funded trials. It might not
hold in industry sponsored tr i a l so nt h eg r o u n d st h a t
industry invest heavily in their drug development pro-
grams, have a better knowledge of which drugs work
and as a result have a better success rate. This, however,
has not been confirmed but is a testable hypothesis. We
would encourage others, particularly industry, to con-
duct such a study.
Conclusions
The results indicate HTA trials are compatible with
equipoise (the new treatment had superior results in
61% of the comparisons 95% CI 49.9% to 71.6%). The
pattern of results in HTA trials is similar to that of the
National Cancer Institute portfolio. Differences that
existed were plausible given the differences in the types
of trials -HTA trials are more pragmatic.
The classification of trials by results developed by
D j u l b e g o v i ci sau s e f u lw a yo fs u m m a r i s i n gt h er e s u l t s
from clinical trials. Our application of it, allows the clas-
sification to be applied to trials with different outcomes.
We look forward to comparisons with other groups of
trials, particularly trials funded by industry.
Additional material
Additional file 1: Breakdown of the number of comparisons
supplied by each trial. A table showing why there are 85 primary
comparisons from the 51 HTA superiority trials
Additional file 2: Characteristics of the 85 comparisons from the 51
included trials. A table showing characteristics of the 85 primary
comparisons included
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